<SEC-DOCUMENT>0001437749-24-024329.txt : 20240801
<SEC-HEADER>0001437749-24-024329.hdr.sgml : 20240801
<ACCEPTANCE-DATETIME>20240801170610
ACCESSION NUMBER:		0001437749-24-024329
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20240729
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240801
DATE AS OF CHANGE:		20240801

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CervoMed Inc.
		CENTRAL INDEX KEY:			0001053691
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				300645032
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37942
		FILM NUMBER:		241167743

	BUSINESS ADDRESS:	
		STREET 1:		20 PARK PLAZA
		STREET 2:		SUITE 424
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		(617) 744-4400

	MAIL ADDRESS:	
		STREET 1:		20 PARK PLAZA
		STREET 2:		SUITE 424
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Diffusion Pharmaceuticals Inc.
		DATE OF NAME CHANGE:	20160115

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RestorGenex Corp
		DATE OF NAME CHANGE:	20140307

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Stratus Media Group, Inc
		DATE OF NAME CHANGE:	20080722
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>crvo20240801_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:rr="http://xbrl.sec.gov/rr/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:crvo="http://www.crvo.com/20240729"><head>
	<title>crvo20240801_8k.htm</title>

	<!-- Generated by ThunderDome Portal - 8/1/2024 8:36:30 PM -->
<meta http-equiv="Content-Type" content="text/html"/></head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none">
<ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="d20248K" name="dei:AmendmentFlag" id="ixv-335">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d20248K" name="dei:EntityCentralIndexKey" id="ixv-336">0001053691</ix:nonNumeric>

</ix:hidden>
<ix:references>
<link:schemaRef xlink:href="crvo-20240729.xsd" xlink:type="simple"/>
</ix:references>
<ix:resources>
<xbrli:context id="d20248K">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2024-07-29</xbrli:startDate>
<xbrli:endDate>2024-07-29</xbrli:endDate>
</xbrli:period>
</xbrli:context>



</ix:resources>
</ix:header>
</div>

<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0"/>
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0"/>
<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>UNITED STATES</b></div>

<div style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Washington, D.C. 20549</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</div>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>FORM <ix:nonNumeric contextRef="d20248K" name="dei:DocumentType" id="ixv-21"><b>8-K</b></ix:nonNumeric></b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</div>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CURRENT REPORT</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Pursuant to Section 13 or 15(d)</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>of The Securities Exchange Act of 1934</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20248K" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="ixv-34"><b>July 29, 2024</b></ix:nonNumeric></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Date of Report (Date of earliest event reported)</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</div>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:24pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20248K" name="dei:EntityRegistrantName" id="ixv-42"><b>CervoMed Inc.</b></ix:nonNumeric></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Exact name of registrant as specified in its charter)</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</div>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: top; width: 32%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20248K" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-54"><b>Delaware</b></ix:nonNumeric></div>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 32%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20248K" name="dei:EntityFileNumber" id="ixv-59"><b>001-37942</b></ix:nonNumeric></div>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 32%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20248K" name="dei:EntityTaxIdentificationNumber" id="ixv-64"><b>30-0645032</b></ix:nonNumeric></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 32%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(State or other jurisdiction</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>of incorporation)</b></div>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 32%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Commission</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>File Number)</b></div>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 32%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(I.R.S. Employer</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Identification No.)</b></div>
			</td>
		</tr>

</tbody></table>

<div style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td colspan="3" style="vertical-align: middle; width: 67%;">&#160;</td>
			<td colspan="2" style="vertical-align: middle; width: 1%;">&#160;</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align: top; width: 67%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20248K" name="dei:EntityAddressAddressLine1" id="ixv-93"><b>20 Park Plaza, Suite 424</b></ix:nonNumeric></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d20248K" name="dei:EntityAddressCityOrTown" id="ixv-97"><b>Boston</b></ix:nonNumeric>, <ix:nonNumeric contextRef="d20248K" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="ixv-99"><b>Massachusetts</b></ix:nonNumeric></b></div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 32%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20248K" name="dei:EntityAddressPostalZipCode" id="ixv-104"><b>02116</b></ix:nonNumeric></div>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align: top; width: 67%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Address of principal executive offices)</b></div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 32%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Zip Code)</b></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Registrant</b>&#8217;<b>s telephone number, including area code: (<ix:nonNumeric contextRef="d20248K" name="dei:CityAreaCode" id="ixv-118"><b>617</b></ix:nonNumeric>) <ix:nonNumeric contextRef="d20248K" name="dei:LocalPhoneNumber" id="ixv-120"><b>744-4400</b></ix:nonNumeric></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Not applicable</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Former name or former address, if changed since last report)</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</div>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><ix:nonNumeric contextRef="d20248K" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="ixv-346">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><ix:nonNumeric contextRef="d20248K" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="ixv-347">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><ix:nonNumeric contextRef="d20248K" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="ixv-348">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><ix:nonNumeric contextRef="d20248K" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="ixv-349">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 32%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Title of each class</b></div>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 32%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Trading</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Symbol(s)</b></div>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 32%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Name of each exchange</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>on which registered</b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 32%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20248K" name="dei:Security12bTitle" id="ixv-350">Common Stock</ix:nonNumeric>, $0.001 par value</div>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 32%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20248K" name="dei:TradingSymbol" id="ixv-351">CRVO</ix:nonNumeric></div>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 32%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20248K" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-352">NASDAQ</ix:nonNumeric> Capital Market</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Emerging growth company&#160;<ix:nonNumeric contextRef="d20248K" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="ixv-353">&#9744;</ix:nonNumeric></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#9744;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<div style="margin: 0pt; text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><b>Item&#160;8.01</b></div>
			</td>
			<td style="width: auto;">
			<div style="margin: 0pt; text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><b>Other Events</b></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On July 29, 2024, CervoMed Inc. (the &#8220;Company&#8221;) issued a press release announcing that plasma biomarker data from the AscenD-LB Phase 2a trial of neflamapimod in patients with dementia with Lewy bodies was featured in a poster presentation at the Alzheimer's Association International Conference&#174; held in Philadelphia, Pennsylvania from July 28-August 1, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On July 30, 2024, the Company issued a press release announcing that Company management will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference, to be held in Boston, Massachusetts, on August 13, 2024. A copy of the press release is attached hereto as Exhibit 99.2 and is incorporated by reference herein.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Item&#160;9.01</b></div>
			</td>
			<td style="width: auto;">
			<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Financial Statements and Exhibits</b></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>(d)</i></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b><i>Exhibits</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:bottom;width:11.5%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Exhibit No.</b></div>
			</td>
			<td style="vertical-align:bottom;width:3.3%;">&#160;</td>
			<td style="vertical-align: bottom; width: 85.2%; border-bottom: 1px solid rgb(0, 0, 0);">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Description</b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:11.5%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">99.1</div>
			</td>
			<td style="vertical-align:top;width:3.3%;">&#160;</td>
			<td style="vertical-align:top;width:85.2%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_707066.htm" style="-sec-extract:exhibit;">Press Release, issued July 29, 2024</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:11.5%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">99.2</div>
			</td>
			<td style="vertical-align:top;width:3.3%;">&#160;</td>
			<td style="vertical-align:top;width:85.2%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_707067.htm" style="-sec-extract:exhibit;">Press Release, issued July 30, 2024</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:11.5%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">104</div>
			</td>
			<td style="vertical-align:top;width:3.3%;">&#160;</td>
			<td style="vertical-align:top;width:85.2%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</div>
			</td>
		</tr>

</tbody></table>

<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&#160;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>SIGNATURES</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tbody><tr>
			<td style="width: 50%; width: 50%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Date: August 1, 2024</div>
			</td>
			<td colspan="2" style="width: 38%; width: 5%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>CervoMed Inc.</b></div>
			</td>
			<td style="width: 12%; width: 12%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"></div>
			</td>
		</tr>
		<tr>
			<td style="width: 50%; width: 50%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"></div>
			</td>
			<td style="width: 3%; width: 5%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"></div>
			</td>
			<td align="left" style="nowrap: nowrap; width: 35%; width: 33%;" valign="bottom">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"></div>
			</td>
			<td style="width: 12%; width: 12%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"></div>
			</td>
		</tr>
		<tr>
			<td align="left" style="width: 50%; text-align: left; width: 50%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"></div>
			</td>
			<td style="width: 3%; text-align: left; width: 5%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><span style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">By: </span></div>
			</td>
			<td align="left" style="nowrap: nowrap; width: 35%; border-bottom: 1px solid rgb(0, 0, 0); width: 33%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><span style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">/s/&#160;</span>William Elder</div>
			</td>
			<td style="width: 12%; width: 12%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"></div>
			</td>
		</tr>
		<tr>
			<td style="width: 50%; width: 50%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"></div>
			</td>
			<td style="width: 3%; width: 5%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Name:</div>
			</td>
			<td style="width: 35%; width: 33%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">William Elder</div>
			</td>
			<td style="width: 12%; width: 12%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"></div>
			</td>
		</tr>
		<tr>
			<td style="width: 50%; width: 50%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"></div>
			</td>
			<td style="width: 3%; width: 5%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Title:&#160;</div>
			</td>
			<td style="width: 35%; width: 33%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;Chief Financial Officer &amp; General Counsel</div>
			</td>
			<td style="width: 12%; width: 12%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 252pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
3
</div>
</div>
</div>


</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex_707066.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head>
	<title>ex_707066.htm</title>

	<!-- Generated by ThunderDome Portal - 8/1/2024 8:34:14 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<div contenteditable="false" data-hf-endpoint="start" data-hf-html="%3Cdiv%20style%3D%22width%3A%20100%25%3B%22%3E%3Cdiv%20class%3D%22hf-row%22%3E%3Cdiv%20class%3D%22hf-cell%20TOCLink%22%20style%3D%22text-align%3A%20left%3B%20margin%3A%200pt%3B%20width%3A%2099.9%25%3B%20display%3A%20inline-block%3B%22%3E%3C%2Fdiv%3E%3C%2Fdiv%3E%3Cdiv%20class%3D%22hf-row%22%3E%3Cdiv%20class%3D%22hf-cell%22%20style%3D%22font-family%3A%20%26quot%3BTimes%20New%20Roman%26quot%3B%2C%20Times%2C%20serif%3B%20font-size%3A%2010pt%3B%20text-align%3A%20left%3B%20margin%3A%200pt%3B%20width%3A%2099.9%25%3B%20display%3A%20inline-block%3B%22%3E%3Cimg%20src%3D%22%2Fhtmleditor%2FImage%2FGetImage%3FprojId%3D107814%26amp%3BimageName%3Dlogosm.jpg%22%3E%3C%2Fdiv%3E%3C%2Fdiv%3E%3C%2Fdiv%3E" data-hf-type="header">&nbsp;</div>

<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 99.1</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font><img alt="logosm.jpg" src="logosm.jpg"></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CervoMed Announces Presentation at AAIC 2024 on Plasma Biomarker Data That Are Consistent with Neflamapimod Impacting the Underlying Disease Process in Patients with Dementia with Lewy bodies (DLB) </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>- Baseline data from the AscenD-LB Phase 2a trial in DLB demonstrated that plasma glial fibrillary acidic protein (GFAP) was highly correlated to scores on the CDR-SB; plasma GFAP shown to increase with neurodegenerative progression in DLB </i>&#8211;<i> </i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>- AscenD-LB Phase 2a results demonstrated neflamapimod treatment led to significant reduction compared to placebo in plasma GFAP levels in patients with DLB and the effects of neflamapimod on plasma GFAP were associated with improvement in CDR-SB - </i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Boston </b>&#8211;<b> July 29, 2024 </b>&#8211; CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that plasma biomarker data from the AscenD-LB Phase 2a trial of neflamapimod in patients with dementia with Lewy bodies (DLB), was featured in a poster presentation at the Alzheimer's Association International Conference&#174; (AAIC), being held in Philadelphia from July 28-August 1, 2024.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#8220;Recent developments in the field support the use of plasma GFAP to evaluate the therapeutic effects on DLB-specific disease processes, and baseline data from AscenD-LB, our Phase 2a trial, further validate the utility of this biomarker,&#8221; said John Alam, MD, Chief Executive Officer of CervoMed. &#8220;We observed a clear association between plasma GFAP and dementia severity in patients with DLB. Additionally, growing data highlights the effects of neflamapimod on GFAP&#8212;particularly its association with the positive effects on clinical outcomes &#8212;and underscore the potential to address the underlying disease process in early-stage DLB. With these critical learnings from the AscenD-LB Phase 2a trial, we believe our fully enrolled RewinD-LB Phase 2b trial is optimized for success and we remain on track to report topline data in December 2024.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The ePoster (91713) is accessible on the conference portal, and additional details are provided below. A PDF copy of the GFAP poster presentation will be available on the &#8220;<u>Presentations and Publications</u>&#8221; section of the CervoMed website.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Title: Neflamapimod treatment reduces plasma glial fibrillary acidic protein GFAP levels in patients with dementia with Lewy bodies (DLB) who do not have co-existing AD co-pathology</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Authors:&nbsp;John Alam, Marleen Koel-Simmelink, Jennifer Conway, Inge Verberk, Charlotte Teunissen; CervoMed Inc (JA and JC) and Amsterdam Medical Center (MKS, IV, CT)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Key Takeaways from the presentation:</b>&nbsp;The effects of neflamapimod on plasma GFAP were evaluated in both the overall and early-stage DLB patient population, and the treatment effects of GFAP correlated to clinical outcomes:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Baseline (BL) plasma GFAP level was highly correlated to the baseline Clinical Dementia Rating Sum of Boxes (CDR-SB) score and was significantly higher in patients with AD Co-Pathology (BL ptau181 &#8805;&nbsp;2.2 pg/mL) compared to patients without AD co-pathology (baseline ptau181 &lt; 2.2 pg/mL). Plasma GFAP was significantly elevated in both groups compared to levels in healthy controls in the literature.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="width: 100%;">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: 99.9%; display: inline-block;">&nbsp;</div>
</div>

<div class="hf-row">
<div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: left; margin: 0pt; width: 99.9%; display: inline-block;"><img src="logosm.jpg" alt="logosm.jpg"></div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In early-stage DLB patients (i.e., patients with pre-treatment plasma ptau181 below the cutoff for AD-related co-pathology), there was a mean 14.1 pg/mL increase in the placebo treatment group (N=13) vs. mean 10.6 pg/mL reduction with neflamapimod treatment (N=15; p=0.04 for the difference). In patients with advanced DLB (i.e., patients with pre-treatment plasma ptau181 above the cutoff for AD-related co-pathology), there was a mean 6.0 pg/mL decrease in the placebo group (N=14) vs. mean 14.0 pg/mL reduction with neflamapimod treatment (N=15; the difference was not significant).</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the early-stage DLB patient population, in participants treated with neflamapimod there was a significant correlation (r=0.54, p=0.04) between the effects of GFAP and clinical outcomes assessed by change from baseline to week 16 in CDR-SB, with increased GFAP being associated with worsening CDR-SB, while reduction in GFAP was associated with improvement on CDR-SB. The correlation was not seen in placebo-recipients (r=0.31, p=NS).</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Recent developments in the field support the use of plasma GFAP as a biomarker of the underlying disease process in DLB:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Data from the Mayo Clinic (Diaz-Galvan et al, 2024) show that in patients with prodromal DLB plasma GFAP is elevated relative to healthy controls, while plasma neurofilament light chain and plasma ptau181 are not. As patients at this stage have cholinergic degeneration in the basal forebrain without significant cortical atrophy (Kantarci et al, 2022), GFAP elevation in this context appears to reflect the disease in the basal forebrain cholinergic system that is the primary driver of disease expression and progression in early-stage DLB (Okkels et al, 2024).</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Data from the European Dementia with Lewy Bodies consortium (Bolsewig et al, 2024), show that in patients with DLB, plasma GFAP is associated with rate of cognitive decline, but not with CSF amyloid status, suggesting that GFAP elevation has potential to evaluate DLB-specific disease processes.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>About the RewinD-LB Phase 2b Study in Dementia with Lewy Bodies </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">CervoMed&#8217;s ongoing Phase 2b study, RewinD-LB, is a randomized, 16-week, double-blind, placebo-controlled clinical trial evaluating oral neflamapimod (40mg TID) in up to 160 patients with very mild or mild dementia due to DLB. Patients completing the 16-week placebo-controlled study period will be able to continue in the study while receiving open label neflamapimod treatment for an additional 32 weeks. Patients with Alzheimer&#8217;s Disease-related co-pathology, assessed by a blood biomarker (plasma ptau181), will be excluded. The primary endpoint in the study is change in the Clinical Dementia Rating Sum of Boxes, and secondary endpoints include the Timed Up and Go test, a cognitive test battery, and the Clinician&#8217;s Global Impression of Change. The RewinD-LB study is funded by a&nbsp;$21.0 million&nbsp;grant from the&nbsp;National Institutes&nbsp;of Health&#8217;s&nbsp;National Institute on Aging, which will be disbursed over the course of the study as costs are incurred. The study includes 43 sites (32 in&nbsp;the United States, eight in the&nbsp;United Kingdom, and three in&nbsp;the Netherlands). More information on the RewinD-LB study, is available at&nbsp;<u>clinicaltrials.gov</u>. The study completed enrollment in June 2024 and topline primary efficacy results are expected in December 2024.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="width: 100%;">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: 99.9%; display: inline-block;">&nbsp;</div>
</div>

<div class="hf-row">
<div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: left; margin: 0pt; width: 99.9%; display: inline-block;"><img src="logosm.jpg" alt="logosm.jpg"></div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Forward-Looking Statements</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">This press release includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, regarding the intentions, plans, beliefs, expectations or forecasts for the future of CervoMed Inc. (the Company), including, but not limited to, the therapeutic potential of neflamapimod, the anticipated timing and achievement of clinical and development milestones, including the completion and achievement of primary endpoints of the RewinD-LB Phase 2b clinical trial and the Company&#8217;s announcement of topline data therefrom, any other expected or implied benefits or results, including that any initial clinical results observed with respect to neflamapimod in the RewinD-LB Trial will be replicated in later trials, and the Company&#8217;s clinical development plans. Terms such as &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;aims,&#8221; &#8220;seeks,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;could,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;approximately,&#8221; &#8220;potential,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;predict,&#8221; &#8220;forecast,&#8221; &#8220;continue,&#8221; or other words that convey uncertainty of future events or outcomes (including the negative of these terms) may identify these forward-looking statements. Although there is believed to be reasonable basis for each forward-looking statement contained herein, forward-looking statements by their nature involve risks and uncertainties, known and unknown, many of which are beyond the Company&#8217;s control and, as a result, actual results could differ materially from those expressed or implied in any forward-looking statement. Particular risks and uncertainties include, among other things, those related to: the Company&#8217;s available cash resources and the availability of additional funds on acceptable terms; the results of the Company&#8217;s clinical trials, including RewinD-LB; the likelihood and timing of any regulatory approval of neflamapimod or the nature of any feedback the Company may receive from the U.S. Food and Drug Administration; the ability to implement business plans, forecasts, and other expectations in the future; general economic, political, business, industry, and market conditions, inflationary pressures, and geopolitical conflicts; and the other factors discussed under the heading &#8220;Risk Factors&#8221; in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the U.S. Securities and Exchange Commission (SEC) on March 29, 2024, and other filings that the Company may file from time to time with the SEC. Any forward-looking statements in this press release speak only as of the date hereof (or such earlier date as may be identified). The Company does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except to the extent required by law.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>References:</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Bolsewig, K., A. van Unnik, E. R. Blujdea, et al, and European-Dementia With Lewy Bodies (2024). "Association of Plasma Amyloid, P-Tau, GFAP, and NfL With CSF, Clinical, and Cognitive Features in Patients With Dementia With Lewy Bodies." <u>Neurology</u> (2024) 102): e209418</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Diaz-Galvan, P., S. A. Przybelski, A. Algeciras-Schimnich, et al. "Plasma biomarkers of Alzheimer's disease in the continuum of dementia with Lewy bodies." <u>Alzheimers Dement</u> (2024) 20:2485-2496</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Kantarci, K., Z. Nedelska, Q. Chen, M. et al. "Longitudinal atrophy in prodromal dementia with Lewy bodies points to cholinergic degeneration." <u>Brain Communications (2022)</u> 4:fcac013</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Okkels, N., M. J. Grothe, J. P. Taylor, et al. "Cholinergic changes in Lewy body disease: implications for presentation, progression and subtypes." <u>Brain</u> (2024) 147:2308-2324.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Investor Contact: </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">PJ Kelleher</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">LifeSci Advisors</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Investors@cervomed.com</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">617-430-7579</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>ex_707067.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<html><head>
	<title>ex_707067.htm</title>

	<!-- Generated by ThunderDome Portal - 8/1/2024 8:34:06 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 99.2</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><img alt="logosm.jpg" src="logosm.jpg"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CervoMed to Participate in The Canaccord Genuity 44</b><b><sup style="vertical-align:top;line-height:120%;">th</sup></b><b> Annual Growth Conference</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Boston </b>&#8211;<b> July 30, 2024 </b>&#8211; CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company&#8217;s Management will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference, to be held in Boston, MA and participate in one-on-one investor meetings.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Presentation Details </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Format: Fireside Chat</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date: Tuesday, August 13, 2024</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Time: 12:30 PM ET</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Webcast Link: https://wsw.com/webcast/canaccord98/crvo/2485318</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The webcast of the fireside chat will be accessible in the Investors section of the CervoMed website https://www.cervomed.com/.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>About CervoMed</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">CervoMed Inc. (the &#8220;Company&#8221;) is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that causes disease in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with DLB.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Investor Contact: </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">PJ Kelleher</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">LifeSci Advisors</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Investors@cervomed.com</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">617-430-7579</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>crvo-20240729.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 8/1/2024 8:36:34 PM-->
<xsd:schema xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:crvo="http://www.crvo.com/20240729" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.crvo.com/20240729">
<xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
<xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd"/>

<xsd:annotation>
<xsd:appinfo>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crvo-20240729_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crvo-20240729_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crvo-20240729_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
<link:roleType id="statement-document-and-entity-information" roleURI="http://www.crvo.com/20240729/role/statement-document-and-entity-information">
<link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:presentationLink</link:usedOn>
</link:roleType>
</xsd:appinfo>
</xsd:annotation>
<xsd:element abstract="true" id="crvo_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>crvo-20240729_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 8/1/2024 8:36:34 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
<link:roleRef roleURI="http://www.crvo.com/20240729/role/statement-document-and-entity-information" xlink:href="crvo-20240729.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:definitionLink xlink:role="http://www.crvo.com/20240729/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>

<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>


<link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>crvo-20240729_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 8/1/2024 8:36:34 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
<link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Type</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Period End Date</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Registrant Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Incorporation, State or Country Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, File Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Tax Identification Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Address Line One</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, City or Town</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, State or Province</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Postal Zip Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:label xlink:label="dei_WrittenCommunications-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:label xlink:label="dei_SolicitingMaterial-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementIssuerTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Emerging Growth Company</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Central Index Key</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>

</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>crvo-20240729_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 8/1/2024 8:36:34 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.crvo.com/20240729/role/statement-document-and-entity-information" xlink:href="crvo-20240729.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:presentationLink xlink:role="http://www.crvo.com/20240729/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>

<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>

<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>logosm.jpg
<TEXT>
begin 644 logosm.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!P17AI9@  34T *@    @ !@$Q  (
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M!/7:MM"RCL !V%?JM_P>!)'9^'O@!:PJL<4-SJ^Q%& JB*V  'H*E_X(#_\
M!%+XP_LH?MO7/Q(^,7@^'PW8^'=!N(-#(U6TO&GO;EEB8XAD<KL@\T9; S(,
M=./9/^#D;_@G3\9/V^C\)1\*?"B>)E\+OJ3:ENU.UL_L_G" 1_ZZ1-V=C?=S
MC'-%?'4I9C22DN6*>MU:[3Z[=@I8>:PD[IW?2VNZ/E3_ (-"O^3J/C!_V*MI
M_P"E=?.O_!R-_P I?_B'_P!@S2/_ $C2OT(_X-R?^"7_ ,;_ -@WX^?$C7/B
MIX.C\,Z;KV@6]C8RKJMI>>=,EQO9<0R.5PO.3@5Y'_P6H_X(H_M&?MC?\%%_
M&7Q ^'_@[3=6\*ZM9:=#:W4VNVEJTC16RI(/+D<,,,".1S13Q5%9I.HYKEY5
MK=6^SU"5&H\$H\KO?:WJ87_!OQ_P5T^!_P#P3\_90\4>%?B=XAU32=:U3Q1+
MJ=O#;:3<7BM T$*!BT:D [D;@\U^C_P"_P""^G[-/[2_QF\.^ ?"/BO6KSQ-
MXJN_L6G02Z#=0)++M9L%V0*O"GDFOQ5_XAL_VO\ _HGNB_\ A46'_P <KW/_
M ()E?\$(/VG/V;O^"@7PG\>>+_!&EZ?X9\+ZX+W4KF+Q!9W#01>3*NX(DA9N
M6' !/-9X["Y?4YZWM/>=W\2WL/#5\5#EI\FFBV>Q[3_P>%?\D\^ _P#V%]6_
M])X*_.__ ((??M;^!_V(/^"@VC_$'XB:A=:7X8L]"U*QEN+>TDNG$LRQB,;(
MP6P=IYQ@5^O'_!R-_P $]_BY^WSX,^$MK\*/"\?B:X\,:CJ$^I(VHVUG]G26
M&)4.9G0-DJPPN<8K\J?^(=/]L+_HE,/_ (4NF?\ Q^MLKK8>6 5&K-*]T]4G
MJWW,\9&K'%.I"+>W1OH?JI^T!_P=2?L\^ O %]<> X?%?C[Q0T3"QL/[*DT^
MU\W'RF:>8#:F<9V*[8Z"OP _:'^/7B+]IGXV>*OB)XPNH[KQ%XNOY-2OY(UV
MQ(S8"QHO9$1511V5!7V7X'_X-G/VN/&%XL=WX1\*>&HRP!FU7Q+;E5'KBW\Y
MN/I7Z+_\$U/^#8GP=^R_XXTOQS\7M?M?B5XHTF1;FPTBVM3%H=A.IRLC*^7N
M64@%=X5 1G8>,.E6R[ 1<J4N9OSNWY::(<J>+Q32FK+[O^">S_\ !N[^Q9J7
M['/_  3MTB3Q%8R:?XJ^(EX_BC4;:6,I-9QRHB6T+@\AEA1&(/1I&':BONRB
MOD,16E6J2JRW;N>[3IJ$%"/0\O\ VV/@[<_M _LB_$CP78X-_P"(O#]W:6@)
MVAIS$QB!/8%PHK\F_P#@C%^T/H_["?Q<N/#_ (AVVN@^+%2TU*^E3#65VA(2
M5NZQY)1AV!!/W37[:5^8_P#P5&_X)::W_P )KJWQ)^&^FR:II^J,;O6-%M4S
M<6LQ^_-"@Y='/S,H^93N(!!POT?#M;"SC4P&,TC4M9]G_GLUZ>9^3^*6#SF@
M\-GV2)REAVW."5^:+\EJTM4TM;._2Z_32UNH[ZVCFADCFAF4/'(C!E=2,@@C
M@@CG(J2OPN_9Y_X*(_%O]D^U_L71=::;2;1BO]CZQ ;B&V/=5#$/%_NJP&>W
M6O:A_P %L?CC\3)H]$\.>&?"BZQ>D1P?V;IES=7+,>!M1I7!.3W4BM:_!N-A
M+W'%Q[WMIY_TSS\N\=LAKT5]8A4A5ZP4>;7LFGKY72?D?IO\6OC1I/PF71[6
MZD6;6O$M]'INCZ<K?OKZ=R,X'41HN7=\855)ZX!["OD7]@;]C?QII7C2;XN?
M&K5+K6OB)J%N8-/M+F02C0H&^]C;\BR,#C:F @)'))Q]=5\]CJ-*C/V5*7-;
M=K9OR\EWZ^A^G9!CL;C:#Q>+I.DI?!!_$H]Y]I2WY?LJR>MPHHHKB/>"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** .-\=_L[> ?BA>?:/$G@GPKKUQG/FW
M^E07$A_X$RDU>\ _!OPC\*K<Q>&?"_A_P_&>HT[3XK;/_?"BBBM/;5''D<G;
MM?0Y8X'#1J^WC3CS][*_WVN=)11169U!1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
(4 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140239109081856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Jul. 29, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity, Registrant Name</a></td>
<td class="text">CervoMed Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document, Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document, Period End Date</a></td>
<td class="text">Jul. 29,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity, Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity, File Number</a></td>
<td class="text">001-37942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity, Tax Identification Number</a></td>
<td class="text">30-0645032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity, Address, Address Line One</a></td>
<td class="text">20 Park Plaza, Suite 424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity, Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity, Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity, Address, Postal Zip Code</a></td>
<td class="text">02116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">744-4400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CRVO<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity, Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity, Central Index Key</a></td>
<td class="text">0001053691<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( ,2( 5D'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " #$B %97DD%2.X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M3L,P#(9?!>7>.NW00%&7"X@32$A, G&+'&^+:-HH,6KW]J1EZX3@ 3C&_O/Y
ML^0&@\(^TG/L T5VE*Y&WW9)8=B( W-0  D/Y$TJ<Z++S5T?O>'\C'L(!C_,
MGJ"6<@V>V%C#!B9@$1:BT(U%A9$,]_&$M[C@PV=L9YA%H)8\=9R@*BL0>IH8
MCF/;P 4PP9BB3]\%L@MQKOZ)G3L@3LDQN24U#$,YK.9<WJ&"MZ?'EWG=PG6)
M38>4?R6G^!AH(\Z37U=W]]L'H6M97Q?RMI#5MJZ47"MY\SZY_O"["/O>NIW[
MQ\9G0=W K[O07U!+ P04    " #$B %9F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M ,2( 5D@>;K0.P0  ),0   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
ME9AK<^(V%(;_BL:=V6EG0GS!0)(",X0D6[J;A :Z.]-./PA;@":VY$IR"/WU
M>V3 IK/FF/T27]!Y_>CHZ)64_D:J5[UFS)#W-!%ZX*R-R6Y<5T=KEE)]*3,F
MX)>E5"DU\*A6KLX4HW$1E"9NX'E=-Z5<.,-^\6ZJAGV9FX0+-E5$YVE*U?:6
M)7(S<'SG\.*%K];&OG"'_8RNV(R9/[.I@B>W5(EYRH3F4A#%E@-GY-_<!J$-
M*%I\X6RCC^Z)[<I"RE?[,(D'CF>)6,(B8R4H7-[8F"6)50*.?_>B3OE-&WA\
M?U!_*#H/G5E0S<8R^<ICLQXX5PZ)V9+FB7F1F]_8OD,=JQ?)1!=_R6;7-NPX
M),JUD>D^& A2+G97^KY/Q%% <"H@V <$!??N0P7E'35TV%=R0Y1M#6KVINAJ
M$0UP7-A1F1D%OW*(,\,[&>609$-&(B;WPG"S)1.Q&VW(6M\U\!';U(WV@K<[
MP>"$X.]Y<DF"ZPL2>$'X_W 7V$K H 0,"KUV$^ 1%?G[,[0B$\-2_4\=XDXR
MK)>TA7ZC,QJQ@0.5K)EZ8\[PPT]^U_L5 6Z7P&U,?;A+X@5Y82NNC:* _D13
M5H>)"XT!3#ZR&'H>72)@80D6HGJ'3%Z0^3:KY<'CKUJ?$(I.2=$YDV+*%)>V
MZ&("I5L+A$N5I=94:]V2K7O6T$'"I<JD*HKM@LP,X!&IR%CFPJ@M7.-:7%S]
M[AY![)6(O;,0'WC"R%.>+IBJ(\%%/,]OM7O788  795 5V<!S>D[F<0PL'S)
MH]TL/8V'2[:]EM<-.UX;X[LN^:[/XAO%,<QU7=Z0PD*>1>U XI*!1Z94O9)I
M0O^C4!XYA_((T0KTO<J/O1_C'5M+AN*;RTV]'>-ZMQ+6$(&A'2T5_H^AE1-C
MJN0;%U%M+AM$'T<86[5*^*BG?\\VA7[3A/S%LY/3M4'2"WR_B\%5*X+?X.1V
M"$>P:3J-@@MT_1X&4JT /F[AGV4$.9FNI<#,HT&D%X:M,/0\C*A:#7S<P[\J
M;@P3D)@TS<7>.70M%2ZTI(EF&%*U"/BX3\]DPB-NN%B11ZAOQ6E2RX.K-/)4
MCN_C;CU5K!5!>AA,L&(G-&<B9HH\+Y<GQ@_7:R2KK-_'C?H[LHG6.9 U N*R
MC8"5]_NX4\^Y@652+HD?_+SXA<Q8E$.];6N9<"5;G["DS8R,7K%=;>7S >[+
M<T5C6V*S;;J0M076(#!^^?*,D52V'N .?,@*N7^/UE2LV,G]:H/0TVAV-_H#
M8SK:])]GY_<I4RN;IH\@8=;6)C(J:@>P0;&IJ(+*S0/<C$=0ZG%1[@\)7=6B
MX *-*)6?![@5'](T!AH%SCZ!>?=./K'Z!.%:'NP*O4Z[>^W7H;E'1TQ[7'^D
M=EPT2=@2U+S+'KBSVIV =P]&9L6I<R$-G&&+VS6C8 NV ?R^E-(<'NQ!MOP_
MQ/ ;4$L#!!0    ( ,2( 5F?H!OPL0(  .(,   -    >&PO<W1Y;&5S+GAM
M;-U7;6O;,!#^*T(_8&YB:N*1&+9 8;"-0O-A7Y58=@1Z\62Y<_KKI[-L)VEU
M9=V'L<VAR=T]NKM'=R>9KEMWDOSAR+DCO9*ZW="C<\W[)&D/1ZY8^\XT7'ND
M,E8QYU5;)VUC.2M;<%(R6=[<9(EB0M-BK3MUIUQ+#J;3;D-O:%*L*Z//EI0&
M@U_*%">/3&[HEDFQMV)8RY20IV!>@N%@I+'$>2I\0Q=@:9\"O @:L!SC**&-
M!6,2,H3O_;C\&3!IK5>%E#/!)0V&8MTPY[C5=UX9%@_&%Q 9Y=VI\0QKRTZ+
MY2T].PP_/LG>V)+;.<V"3J9B+7D%=*RHC_#K3), Z)Q17B@%JXUF X?)8Q1\
MV .7\@%:^*VZBMU7)/3B4PEM(+#52?2$1C&$"0K$OXP68E^$O?VML*01C\9]
M[/QN]*!_[XSC]Y97HA_TOIKS8]$7>'36-/+T08I:*Q[V_LL)BS6;_,C16/'D
ML\&D'+R!6TH>N77B<&GY85FSX[V;IJFO<,[+?Y#SGZUSS36W3%Z2]J/_-U?Y
M+8R3\?1<'-&K SI;"5R$&_H5[E=YYD#VG9!.Z%$[BK+D^L4Y]>$=V_L+_"J^
M7U_RBG72[69P0\_R%UZ*3N7SJGNHR[CJ+'^&^VB1S;>PSR5TR7M>;D?5UOM!
M)%[P6<<'')XC=\,31S"?@,41P+ \& /,)WAA>?ZG_:S0_00,X[:*(BO49X7Z
M!*\8LAT^6)ZX3^Z?^$[S/$VS#*OH=AMEL,7JEF7P%X^&<0,/+ ]D>ENM\6[C
M$_+Z'& ]?6U"L)WBDXCM%*\U(/&Z@4>>Q[N-Y0$/K O8[$#^>!Z8J;A/FD)7
M,6[8"<:1/,<0F,7XC&894IT,/O'^8*<D3?,\C@ 69Y"F& *G$4<P!L !0])T
M> \^>Q\ETWLJ.?]74_P$4$L#!!0    ( ,2( 5F7BKL<P    !,"   +
M7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_
MK]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?2
M0$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-
MTG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z
M6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ Q(@!63JJHN=  0
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M?P%02P$"% ,4    " #$B %9!T%-8H$   "Q    $               @ $
M    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( ,2( 5E>205([@   "L"
M   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0
M   ( ,2( 5F97)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M
M92]T:&5M93$N>&UL4$L! A0#%     @ Q(@!62!YNM [!   DQ   !@
M         ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0
M   ( ,2( 5F?H!OPL0(  .(,   -              "  7X,  !X;"]S='EL
M97,N>&UL4$L! A0#%     @ Q(@!69>*NQS     $P(   L
M ( !6@\  %]R96QS+RYR96QS4$L! A0#%     @ Q(@!63JJHN=  0  / (
M  \              ( !0Q   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (
M ,2( 5DD'INBK0   /@!   :              "  ; 1  !X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( ,2( 5EED'F2&0$  ,\#   3
M              "  942  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )
-  D /@(  -\3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="crvo20240801_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crvo.com/20240729/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>crvo-20240729.xsd</File>
    <File>crvo-20240729_def.xml</File>
    <File>crvo-20240729_lab.xml</File>
    <File>crvo-20240729_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="crvo20240801_8k.htm">crvo20240801_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "crvo20240801_8k.htm": {
   "nsprefix": "crvo",
   "nsuri": "http://www.crvo.com/20240729",
   "dts": {
    "schema": {
     "local": [
      "crvo-20240729.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "crvo-20240729_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "crvo-20240729_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "crvo-20240729_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "crvo20240801_8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 26,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://www.crvo.com/20240729/role/statement-document-and-entity-information",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "d20248K",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20240801_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d20248K",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20240801_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.crvo.com/20240729/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.crvo.com/20240729/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.crvo.com/20240729/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.crvo.com/20240729/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document, Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.crvo.com/20240729/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document, Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.crvo.com/20240729/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.crvo.com/20240729/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.crvo.com/20240729/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.crvo.com/20240729/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.crvo.com/20240729/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.crvo.com/20240729/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.crvo.com/20240729/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.crvo.com/20240729/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.crvo.com/20240729/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.crvo.com/20240729/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.crvo.com/20240729/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.crvo.com/20240729/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.crvo.com/20240729/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.crvo.com/20240729/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.crvo.com/20240729/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.crvo.com/20240729/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.crvo.com/20240729/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.crvo.com/20240729/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.crvo.com/20240729/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.crvo.com/20240729/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001437749-24-024329-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-24-024329-xbrl.zip
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MG1_C*:=Q8R&>PX0RU7];G2@YVH44>/'O?=$A1CUAIZXXF5'>\W7%>R9<A8N
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M5 )V82ZK9)AEHV#-%X6NW]8C%%L32Z[>S7WKY8W\T1R#ON>-1ZOG<:3(R5G
M<M#)@%Y,<#L>-PX-;%H@OT_#GAH5MZ1P/Y:"#=;BOI*#]L6VUO6S"HFM)0 1
MOKL&$-6"@)B&:26P',I K&8;;$E!?HL>::;!YAX-YTS#0[^8MX[O8C/=(QX
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M.N0]+DFEDK4 RXX^(1._[Z/O&)O?$J7&<>_5.*XQHQ;,F%$1;1%+;LJ*<7<
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MG"@MK#DI"E\BEL6_,['V/U!+ P04    " #$B %9!T) '7L5   !5P  #0
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MP'8J.2:A_:($WVLA26NG%\S%S=G)%J$(@3JXJO^RU^![2/52 !4>5K"?1?^
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M#)C<F-SG*%P+:RRJQL[Y'WG%DZ5\)&S%Q1>4Y(@"/87W$OGV#F"[6)V0YV4
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MIZS_K*U/_4?K3GD9 7^0?(-#^:=O_Q]02P,$%     @ Q(@!60[EM$WY!
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MM3MZ;_8]T+0)?J0)!C6?/8 E6<GH_";G";=P?-SJ#L-D- S=*OHI1P=?:I7
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M,.,:#<_0%68+]-A'2$0!?RS\3A=($'(4F9-:^[$)5V-2+[N/244\4)(>][9
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M-S(Y+GAS9%!+ 0(4 Q0    ( ,2( 5DRB<&FV 0  .0L   5
M  "  98#  !C<G9O+3(P,C0P-S(Y7V1E9BYX;6Q02P$"% ,4    " #$B %9
M6&2<=?D%  !"/   %0              @ &A"   8W)V;RTR,#(T,#<R.5]L
M86(N>&UL4$L! A0#%     @ Q(@!6== F29T!   ?"T  !4
M ( !S0X  &-R=F\M,C R-# W,CE?<')E+GAM;%!+ 0(4 Q0    ( ,2( 5EI
M:9CSH1   .YW   3              "  703  !C<G9O,C R-# X,#%?.&LN
M:'1M4$L! A0#%     @ Q(@!60="0!U[%0   5<   T              ( !
M1B0  &5X7S<P-S V-BYH=&U02P$"% ,4    " #$B %9#N6T3?D$  "<$0
M#0              @ 'L.0  97A?-S W,#8W+FAT;5!+!08     !P ' +\!
(   0/P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>crvo20240801_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="crvo-20240729.xsd" xlink:type="simple"/>
    <context id="d20248K">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
        </entity>
        <period>
            <startDate>2024-07-29</startDate>
            <endDate>2024-07-29</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="d20248K" id="ixv-335">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="d20248K" id="ixv-336">0001053691</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="d20248K" id="ixv-21">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="d20248K" id="ixv-34">2024-07-29</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="d20248K" id="ixv-42">CervoMed Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="d20248K" id="ixv-54">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="d20248K" id="ixv-59">001-37942</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="d20248K" id="ixv-64">30-0645032</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d20248K" id="ixv-93">20 Park Plaza, Suite 424</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d20248K" id="ixv-97">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d20248K" id="ixv-99">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d20248K" id="ixv-104">02116</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d20248K" id="ixv-118">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d20248K" id="ixv-120">744-4400</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="d20248K" id="ixv-346">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="d20248K" id="ixv-347">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="d20248K" id="ixv-348">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="d20248K" id="ixv-349">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="d20248K" id="ixv-350">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d20248K" id="ixv-351">CRVO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d20248K" id="ixv-352">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="d20248K" id="ixv-353">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
